FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3506-3519

  Choi, Eun Jung ^a   Seo, Eun Jin ^a   Kim, Dae Kyoung ^a   Lee, Su In ^a   Kwon, Yang Woo ^a   Jang, Il Ho ^a   Kim, Ki Hyung ^a   Suh, Dong Soo ^a   Kim, Jae Ho ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Yangsan Hospital   (South Korea)

Author keywords

Cancer stem cells; Epithelial ovarian cancer; FOXP1

Indexed keywords

CISPLATIN; PACLITAXEL; ABCG2 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BREAST CANCER RESISTANCE PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP1 PROTEIN, HUMAN; MESSENGER RNA; NANOG PROTEIN, HUMAN; OCTAMER TRANSCRIPTION FACTOR 4; POU5F1 PROTEIN, HUMAN; REPRESSOR PROTEIN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX; TUMOR PROTEIN;

ABCG2 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CELL MIGRATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FOXP1 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; MALE; MOUSE; NANOG GENE; NONHUMAN; OCT4 GENE; ONCOGENE; OVARIAN CANCER CELL LINE; OVARY CANCER; PROMOTER REGION; SOX2 GENE; TUMOR SPHEROID; TUMOR VOLUME; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ATP BINDING CASSETTE TRANSPORTER, SUB-FAMILY G, MEMBER 2; BLOTTING, WESTERN; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOG HOMEOBOX PROTEIN; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOXB1 TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962206744     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6510     Document Type: Article

References (35)

1. Liao J, Qian F, Tchabo N, Mhawech-Fauceglia P, Beck A, Qian Z, Wang X, Huss WJ, Lele SB, Morrison CD and Odunsi K. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PloS one. 2014; 9:e84941.
2. Cannistra SA. Cancer of the ovary. The New England journal of medicine. 2004; 351:2519-2529.
3. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer research. 2008; 68:4311-4320.
4. Hu L, McArthur C and Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. British journal of cancer. 2010; 102:1276-1283.
5. Silva IA, Bai S, McLean K, Yang K, Griffith K, Thomas D, Ginestier C, Johnston C, Kueck A, Reynolds RK, Wicha MS and Buckanovich RJ. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer research. 2011; 71:3991-4001.
6. Bapat SA, Mali AM, Koppikar CB and Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer research. 2005; 65:3025-3029.
7. Garson K and Vanderhyden BC. Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm. Reproduction. 2015; 149:R59-70.
8. Walters Haygood CL, Arend RC, Straughn JM and Buchsbaum DJ. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World journal of stem cells. 2014; 6:441-447.
9. Ffrench B, Gasch C, O'Leary JJ and Gallagher MF. Developing ovarian cancer stem cell models: laying the pipeline from discovery to clinical intervention. Molecular cancer. 2014; 13:262.
10. Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK, Alvarez M, Talukder S, Pan Q, Mazzoni EO, Nedelec S, Wichterle H, Woltjen K, Hughes TR, Zandstra PW, Nagy A, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell. 2011; 147:132-146.
11. Zhang Y, Zhang S, Wang X, Liu J, Yang L, He S, Chen L and Huang J. Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma. Journal of clinical pathology. 2012; 65:528-533.
12. Jiang W, Li L, Tang Y, Zhang WY, Liu WP and Li GD. Expression of FOXP1 in mucosa-associated lymphoid tissue lymphoma suggests a large tumor cell transformation and predicts a poorer prognosis in the positive thyroid patients. Medical oncology. 2012; 29:3352-3359.
13. Feng J, Zhang X, Zhu H, Wang X, Ni S and Huang J. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. American journal of clinical pathology. 2012; 138:230-235.
14. Toma MI, Weber T, Meinhardt M, Zastrow S, Grimm MO, Fussel S, Wirth MP and Baretton GB. Expression of the Forkhead transcription factor FOXP1 is associated with tumor grade and Ki67 expression in clear cell renal cell carcinoma. Cancer investigation. 2011; 29:123-129.
15. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Harris AL and Banham AH. Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2006; 19:9-16.
16. Takayama K, Horie-Inoue K, Ikeda K, Urano T, Murakami K, Hayashizaki Y, Ouchi Y and Inoue S. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochemical and biophysical research communications. 2008; 374:388-393.
17. Takayama K, Suzuki T, Tsutsumi S, Fujimura T, Takahashi S, Homma Y, Urano T, Aburatani H and Inoue S. Integrative Analysis of FOXP1 Function Reveals a Tumor-Suppressive Effect in Prostate Cancer. Molecular endocrinology. 2014; 28:2012-2024.
18. Lendahl U, Lee KL, Yang H and Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nature reviews Genetics. 2009; 10:821-832.
19. Brown PJ, Ashe SL, Leich E, Burek C, Barrans S, Fenton JA, Jack AS, Pulford K, Rosenwald A and Banham AH. Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL. Blood. 2008; 111:2816-2824.
20. Banham AH, Beasley N, Campo E, Fernandez PL, Fidler C, Gatter K, Jones M, Mason DY, Prime JE, TrougouboffP, Wood K and Cordell JL. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer research. 2001; 61:8820-8829.
21. Koon HB, Ippolito GC, Banham AH and Tucker PW. FOXP1: a potential therapeutic target in cancer. Expert opinion on therapeutic targets. 2007; 11:955-965.
22. Kim YS, Hwan JD, Bae S, Bae DH and Shick WA. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC cancer. 2010; 10:576.
23. Hu Z, Zhu L, Gao J, Cai M, Tan M, Liu J and Lin B. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015; 36:7269-7275
24. Hu Z, Zhu L, Tan M, Cai M, Deng L, Yu G, Liu D, Liu J and Lin B. The expression and correlation between the transcription factor FOXP1 and estrogen receptors in epithelial ovarian cancer. Biochimie. 2015; 109:42-48.
25. Zhu L, Hu Z, Liu J, Gao J and Lin B. Gene expression profile analysis identifies metastasis and chemoresistance-associated genes in epithelial ovarian carcinoma cells. Medical oncology. 2015; 32:426.
26. Shigekawa T, Ijichi N, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T and Inoue S. FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer. Hormones & cancer. 2011; 2:286-297.
27. Gomez GG, Volinia S, Croce CM, Zanca C, Li M, Emnett R, Gutmann DH, Brennan CW, Furnari FB and Cavenee WK. Suppression of microRNA-9 by mutant EGFR signaling upregulates FOXP1 to enhance glioblastoma tumorigenicity. Cancer research. 2014; 74:1429-1439.
28. van Boxtel R, Gomez-Puerto C, Mokry M, Eijkelenboom A, van der Vos KE, Nieuwenhuis EE, Burgering BM, Lam EW and Coffer PJ. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell death and differentiation. 2013; 20:1219-1229.
29. Yan HC, Fang LS, Xu J, Qiu YY, Lin XM, Huang HX and Han QY. The identification of the biological characteristics of human ovarian cancer stem cells. European review for medical and pharmacological sciences. 2014; 18:3497-3503.
30. Flesken-Nikitin A, Hwang CI, Cheng CY, Michurina TV, Enikolopov G and Nikitin AY. Ovarian surface epithelium at the junction area contains a cancer-prone stem cell niche. Nature. 2013; 495:241-245.
31. Bareiss PM, Paczulla A, Wang H, Schairer R, Wiehr S, Kohlhofer U, Rothfuss OC, Fischer A, Perner S, Staebler A, Wallwiener D, Fend F, Fehm T, Pichler B, Kanz L, Quintanilla-Martinez L, et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer research. 2013; 73:5544-5555.
32. Januchowski R, Wojtowicz K and Zabel M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2013; 67:669-680.
33. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, KlingenhoffA, Frisch M, Bayerlein M and Werner T. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005; 21:2933-2942.
34. Cicatiello L, Mutarelli M, Grober OM, Paris O, Ferraro L, Ravo M, Tarallo R, Luo S, Schroth GP, Seifert M, Zinser C, Chiusano ML, Traini A, De Bortoli M and Weisz A. Estrogen receptor alpha controls a gene network in luminallike breast cancer cells comprising multiple transcription factors and microRNAs. The American journal of pathology. 2010; 176:2113-2130.
35. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M and LeCluyse EL. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem. 2003; 278:14146-14152.